XM không cung cấp dịch vụ cho cư dân của Mỹ.
T
T

Teva


Tin tức

Teva Pharma's listed shares up after company lifts 2024 forecasts

BUZZ-Teva Pharma's US-listed shares up after company lifts 2024 forecasts ** U.S.-listed shares TEVA.N of Israel-based Teva Pharmaceutical rise 4.5% to $17.2 premarket ** Company raises its FY forecasts as it benefits from strong demand for its cheaper generic medicines and branded treatment for Huntington's disease (HD) ** TEVA is banking on its b
T

Teva Pharmaceutical Industries Ltd reports results for the quarter ended in June - Earnings Summary

Teva Pharmaceutical Industries Ltd reports results for the quarter ended in June - Earnings Summary Teva Pharmaceutical Industries Ltd TEVA.TA reported quarterly adjusted earnings of 61 cents​​ per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of 56 cents. The mean expectation of four analysts for the quarter was for earnings of 57 cents per share.
T

Teva boosts forecasts as sales of generics, Huntington's disease drug jump

UPDATE 3-Teva boosts forecasts as sales of generics, Huntington's disease drug jump Adds details from conference call in paragraphs 4,5,6 and 7; analyst comment in paragraph 15, graphic By Bhanvi Satija and Michael Erman July 31 (Reuters) - Teva Pharmaceutical Industries TEVA.N raised its annual forecasts on Wednesday, banking on strong demand for its cheaper copycat medicines, including a GLP-1 generic, and branded treatment for Huntington's disease.
T

Teva Pharma lifts annual profit view on strong generic, Huntington's disease drug sales

Teva Pharma lifts annual profit view on strong generic, Huntington's disease drug sales July 31 (Reuters) - Teva Pharmaceutical Industries TEVA.N raised its full-year profit forecast on Wednesday, banking on strength in its generic drug business and strong sales of its Huntington's disease drug. Teva now expects its profit for the full year 2024 to be between $2.30 and $2.50 per share, compared with its previous expectation of $2.20-$2.50 per share.
T

Teva Pharmaceutical Industries Ltd <TEVA.N> expected to post earnings of 55 cents a share - Earnings Preview

Teva Pharmaceutical Industries Ltd expected to post earnings of 55 cents a share - Earnings Preview Teva Pharmaceutical Industries Ltd TEVA.N , TEVA.K is expected to show a rise in quarterly revenue when it reports results on July 31 for the period ending June 30 2024 The Tel Aviv-yafo Israel-based company is expected to report a 4.6% increase in revenue to $4.056 billion from $3.88 billion a year ago, according to the mean estimate from 6 analysts, based on LSEG data.
T

Court weighs what US must prove in Regeneron kickback case

Court weighs what US must prove in Regeneron kickback case By Nate Raymond July 22 (Reuters) - The U.S. Department of Justice on Monday urged a federal appeals court to overturn a judge's ruling that made it tougher for the government to win a lawsuit against Regeneron Pharmaceuticals REGN.O and prove the drugmaker engaged in an illegal kickback scheme.
R
T

Teva Announces First Phase 3 Evidence Of Efficacy And Safety Of An Anti-Cgrp Monoclonal Antibody In Children In Ajovy® (Fremanezumab) Space Trial For Prevention Of Episodic Migraine

BRIEF-Teva Announces First Phase 3 Evidence Of Efficacy And Safety Of An Anti-Cgrp Monoclonal Antibody In Children In Ajovy® (Fremanezumab) Space Trial For Prevention Of Episodic Migraine July 18 (Reuters) - Teva Pharmaceutical Industries Ltd TEVA.TA : TEVA ANNOUNCES FIRST PHASE 3 EVIDENCE OF EFFICACY AND SAFETY OF AN ANTI-CGRP MONOCLONAL ANTIBODY
T

US DOJ drops Viatris unit Mylan from industry-wide antitrust probe

UPDATE 2-US DOJ drops Viatris unit Mylan from industry-wide antitrust probe Adds background in paragraphs 2,5 and 6, updates share movement July 2 (Reuters) - Viatris VTRS.O u nit Mylan is no longer a subject of the U.S. Department of Justice's antitrust investigation into alleged price fixing in the generic drug industry , the parent company said on Tuesday.
P
T

FTC starts probe into Teva about some products' patents, Washington Post reports

UPDATE 2-FTC starts probe into Teva about some products' patents, Washington Post reports Adds Teva comment in penultimate paragraph, background in last paragraph July 1 (Reuters) - The U.S. Federal Trade Commission has opened an investigation into Teva Pharmaceutical TEVA.TA over the company's refusal to take down about two dozen patents for its asthma and COPD inhalers, the Washington Post reported on Monday, citing agency documents.
T

Drugmaker Servier loses EU court fight over pay-for-delay deals

UPDATE 1-Drugmaker Servier loses EU court fight over pay-for-delay deals Adds details By Foo Yun Chee BRUSSELS, June 27 (Reuters) - French drugmaker Servier on Thursday lost its court battle against a European Union fine for deals with rivals to delay sales of generic copies of its top-selling blood pressure medicine perindopril. The European Commission fined Servier 331 million euros ($354 million) in 2014 - and also fined generic drugmakers Teva TEVA.TA , Unichem and its subsidiary Niche, Matr
T

EU top court rejects Servier appeal against EU antitrust fine

EU top court rejects Servier appeal against EU antitrust fine BRUSSELS, June 27 (Reuters) - Europe's top court on Thursday rejected French drugmaker Servier's appeal against a finding by EU antitrust regulators a decade ago that its pay-for-delay deals with generic rivals were anti-competitive. "The Court dismisses the appeals of Lupin, Niche Generics, Unichem Laboratories, Matrix, Teva and Biogaran.
T

Alert wrongly tagged to Teva Pharmaceutical withdrawn

ADVISORY-Alert wrongly tagged to Teva Pharmaceutical withdrawn An alert on Deckers Brands' DECK.N unit Teva was incorrectly tagged to Teva Pharmaceutical Industries TEVA.TA , TEVA.N , an unrelated company, and has been withdrawn. There will be no substitute. STORY_NUMBER: nTUABMJBL2 STORY_DATE: June 26, 2024 STORY_TIME: 01:00:13 PM GMT
T

Teva Reaches Agreement With The Israel Tax Authority To Resolve All Pending Litigation For The Company's Taxable Years 2008-2020

BRIEF-Teva Reaches Agreement With The Israel Tax Authority To Resolve All Pending Litigation For The Company's Taxable Years 2008-2020 June 25 (Reuters) - Teva Pharmaceutical Industries Ltd TEVA.TA : TEVA REACHES AGREEMENT WITH THE ISRAEL TAX AUTHORITY TO RESOLVE ALL PENDING LITIGATION FOR THE COMPANY'S TAXABLE YEARS 2008-2020 TEVA: WILL PAY A TOTA
T

Teva settles tax dispute in Israel with $750 mln payment

UPDATE 1-Teva settles tax dispute in Israel with $750 mln payment Adds details in paragraphs 3 & 4 June 25 (Reuters) - Teva Pharmaceutical Industries TEVA.TA has entered into a deal with the Israel Tax Authority to resolve all pending litigation related to taxes payable for the years from 2008 to 2020, the drugmaker said on Tuesday. Under the agreement, Teva will pay $750 million in installments between 2024 and 2029. In future, if Teva pays dividends on, or repurchases, its equity interests, th
T

Teva reaches agreement to resolve pending tax litigations for $750 million

Teva reaches agreement to resolve pending tax litigations for $750 million June 25 (Reuters) - Teva Pharmaceutical Industries TEVA.TA said on Tuesday it has entered an agreement with the Israel Tax Authority to resolve all pending litigation regarding taxes payable for the years from 2008 to 2020. Under the agreement, the Israel-based company will
T

US law firm Motley Rice appeals $396 mln opioid fee award

US law firm Motley Rice appeals $396 mln opioid fee award By Brendan Pierson June 24 (Reuters) - U.S. law firm Motley Rice is appealing its award of $396 million for its work on litigation against the drug industry over the opioid crisis that resulted in $46 billion in nationwide settlements. The firm said it would appeal the award, which represents 18.6% of a $2.13 billion pool of fees to be divided among dozens of law firms, in a notice filed Friday in Cleveland federal court.
T
W
M

Teva launches generic version of Novo Nordisk's diabetes drug Victoza

UPDATE 2-Teva launches generic version of Novo Nordisk's diabetes drug Victoza Adds details on Victoza in paragraphs 4 to 6 June 24 (Reuters) - Teva Pharmaceuticals TEVA.TA said on Monday it had launched a generic version of Novo Nordisk's NOVOb.CO Victoza to treat patients with type 2 diabetes, making it the first generic GLP-1 drug in the United States where the drug class has seen overwhelming demand .
H
T

Teva launches generic version of Novo Nordisk's diabetes drug Victoza

Teva launches generic version of Novo Nordisk's diabetes drug Victoza June 24 (Reuters) - Teva Pharmaceuticals TEVA.TA said on Monday it has launched the generic version of Danish drugmaker Novo Nordisk's NOVOb.CO drug Victoza to treat patients with type 2 diabetes. The U.S. Food and Drug Administration on Friday tentatively approved London-based Hikma Pharmaceuticals' HIK.L version of Victoza, according to the agency's website.
H
T

Teva Announces Launch Of Authorized Generic Of Victoza In The U.S.

BRIEF-Teva Announces Launch Of Authorized Generic Of Victoza In The U.S. June 24 (Reuters) - Teva Pharmaceutical Industries Ltd TEVA.TA : TEVA ANNOUNCES LAUNCH OF AUTHORIZED GENERIC OF VICTOZA® (LIRAGLUTIDE INJECTION 1.8MG), IN THE UNITED STATES TEVA: LIRAGLUTIDE INJECTION IS INDICATED TO IMPROVE GLYCEMIC CONTROL IN ADULTS AND PEDIATRIC PATIENTS A
T

Drugmaker Apotex accuses Amarin of Vascepa monopoly in US lawsuit

Drugmaker Apotex accuses Amarin of Vascepa monopoly in US lawsuit By Mike Scarcella June 17 (Reuters) - Drugmaker Apotex has sued its rival Amarin > in federal court in New Jersey, accusing it of thwarting competition for a generic version of its heart drug Vascepa and causing wholesalers and other buyers to pay artificially higher prices. The lawsuit , filed on Friday, said Amarin “has engaged in a calculated anticompetitive scheme” for more than a decade to protect Vascepa from drugmakers
B
T



Các điều kiện

Các tài sản phổ thông

Khước từ trách nhiệm: các tổ chức thuộc XM Group chỉ cung cấp dịch vụ khớp lệnh và truy cập Trang Giao dịch trực tuyến của chúng tôi, cho phép xem và/hoặc sử dụng nội dung có trên trang này hoặc thông qua trang này, mà hoàn toàn không có mục đích thay đổi hoặc mở rộng. Việc truy cập và sử dụng như trên luôn phụ thuộc vào: (i) Các Điều kiện và Điều khoản; (ii) Các Thông báo Rủi ro; và (iii) Khước từ trách nhiệm toàn bộ. Các nội dung như vậy sẽ chỉ được cung cấp dưới dạng thông tin chung. Đặc biệt, xin lưu ý rằng các thông tin trên Trang Giao dịch trực tuyến của chúng tôi không phải là sự xúi giục, mời chào để tham gia bất cứ giao dịch nào trên các thị trường tài chính. Giao dịch các thị trường tài chính có rủi ro cao đối với vốn đầu tư của bạn.

Tất cả các tài liệu trên Trang Giao dịch trực tuyến của chúng tôi chỉ nhằm các mục đích đào tạo/cung cấp thông tin và không bao gồm - và không được coi là bao gồm - các tư vấn tài chính, đầu tư, thuế, hoặc giao dịch, hoặc là một dữ liệu về giá giao dịch của chúng tôi, hoặc là một lời chào mời, hoặc là một sự xúi giục giao dịch các sản phẩm tài chính hoặc các chương trình khuyến mãi tài chính không tự nguyện.

Tất cả nội dung của bên thứ ba, cũng như nội dung của XM như các ý kiến, tin tức, nghiên cứu, phân tích, giá cả, các thông tin khác hoặc các đường dẫn đến trang web của các bên thứ ba có trên trang web này được cung cấp với dạng "nguyên trạng", là các bình luận chung về thị trường và không phải là các tư vấn đầu tư. Với việc các nội dung đều được xây dựng với mục đích nghiên cứu đầu tư, bạn cần lưu ý và hiểu rằng các nội dung này không nhằm mục đích và không được biên soạn để tuân thủ các yêu cầu pháp lý đối với việc quảng bá nghiên cứu đầu tư này và vì vậy, được coi như là một tài liệu tiếp thị. Hãy chắc chắn rằng bạn đã đọc và hiểu Thông báo về Nghiên cứu Đầu tư không độc lập và Cảnh báo Rủi ro tại đây liên quan đến các thông tin ở trên.

Cảnh báo rủi ro: Vốn của bạn bị rủi ro. Các sản phẩm có đòn bẩy có thể không phù hợp với tất cả mọi người. Hãy xem kỹ Thông báo rủi ro của chúng tôi.